INTRODUCTION
There has been much recent interest in the possible utility of enzyme replacement therapy for genetic disease (1) (2) (3) (4) (5) (6) 3.2.1.31) has several features that make it attractive as a model disease for the study of enzyme replacement therapy. This deficiency produces a mucopolysaccharide storage disease, several cases of which have been recently recognized (7) (8) (9) (10) . Cultured fibroblasts from these patients show exaggerated accumulation of 35S-mucopolysaccharide, corrected by added ,/-glucuronidase (11) . The human enzyme is remarkably stable and can be isolated with relative ease from a number of different organ sources (12) . However, the corrective potency of the human enzyme for cultured f3-glucuronidase-deficient fibroblasts varies widely, depending on the organ source (12) . Thus, there appear to be different uptake forms of the enzyme.
It is not known whether or not /3-glucuronidasedeficient patients produce a protein molecule that antigenically cross-reacts with normal f3-glucuronidase. Low levels of 8-glucuronidase catalytic activity have been detected in extracts of cultured fibroblasts of deficient patients (8, 13) . While this could represent normal or mutant human /3-glucuronidase, it could also represent nonspecific activity of another lysosomal hydrolase or activity of bovine /-glucuronidase taken up by deficient fibroblasts from fetal calf serum in the culture medium. The ability of deficient patients to produce antigenically cross-reactive material (CRM)1 could be important with respect to the success and safety of enzyme replacement therapy in these patients (14) . Patients with no CRM would be more likely to develop antibodies to infused enzyme that would limit (17) . After mixing at 4°C overnight, the immune IgG-Sepharose was washed successively with 0.15 M NaCl, 1 M NaCl, and water. The enzyme was then eluted with 6 M urea. This eluate was made 3 M in urea and 0.02 M in potassium phosphate, pH 5.8, and centrifuged at 1,000 g for 10 min. The supernatant was applied to a carboxymethyl-Sephadex column suspended in the phosphate buffer and gradient-eluted with 0.13 M potassium phosphate, pH 7.2. The eluate contained partially purified ,3glucuroni-dase. After addition of 1 g glycerolV9 ml enzyme solution to afford cryoprotection, the preparation was stored in aliquots at -70°C. This preparation was used for immunization ofanimals and as standard blocking enzyme and standard indicator enzyme (see below).
Crude placenta, liver, and platelet enzyme were prepared by suspending each tissue in 0.02 M Tris-HCl, 0.075 M NaCl, pH 7.5, and homogenizing the suspension in a Polytron homogenizer (Brinkmann Instruments, Inc., Westbury, N.Y.).
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Triton X-100 was added to the homogenate at a ratio of 0.2 g/ 100 ml, and the homogenate was centrifuged at 100,000 g for 30 min. The supernatant was recovered. After addition of 0.1 vol of 50% glycerol, the enzyme was stored in aliquots at -70°C for use in immunoassay. Fibroblast enzyme was obtained from extracts of cultured fibroblasts. These cells were established in culture from skin biopsies from normal control patients. They were grown to confluence in 1,330-cm2 glass roller bottles for 14 days after a 1:5 split, with Eagle's minimal essential medium containing 15% heat-inactivated (600C for 60 min) fetal calf serum, 100 u/ml penicillin, 100 ,g/ml streptomycin, and 15 mM Hepes buffer, pH 7.6. Fibroblasts were washed twice with 50 ml of phosphate-buffered saline, removed from the bottles by scraping, sedimented, resuspended in an equal volume of 0.01 M Tris-HCl, pH 7.5, containing 0.2% Triton X-100, and broken by sonication. The high-speed supernatant (100,000 g for 1 h) was assayed for protein and lysosomal enzyme concentration as previously described (13) . After addition of 0.1 vol of 50% glycerol, the enzyme was stored in aliquots at -70°C for use in immunoassay.
Patient Animal /3glucuronidase. Fresh liver tissue was obtained from various animals, including sheep, rabbit, rat, and calf. Liver enzyme was prepared as described above for human liver enzyme.
Preparation of antiserum. Antiserum was prepared in a goat by the subcutaneous injection of 40,000 U (166 ,ug) of the partially purified normal human placenta ,/-glucuronidase emulsified in complete Freund's adjuvant. The goat was boosted with the same dose of antigen emulsified in incomplete Freund's adjuvant on day 32, with 9,000 U on days 60 and 104, and with 4,500 U on day 132. The antiserum used in this study was harvested on day 141. Immunodiffusion in agarose gel ofthis antiserum against the partially purified antigen gave two precipitin lines. One precipitin line stained specifically for /8-glucuronidase activity by the simultaneous diazo coupling method of Hayashi et al. (18 (13), there is no simple relationship between ,3-glucuronidase activity (and presumably CRM) and protein in extracts from normal cultured fibroblasts. Plotting blocking activity against the amount of j3glucuronidase activity in the extracts was possible in all of the studies presented, because even the extracts from homozygous deficient patients had some residual ,-glucuronidase activity. However, if this assay was used for extracts with no measurable -glucuronidase activity, the blocking activity could be plotted against protein (bearing the above reservation in mind) or against catalytic activity of another lysosomal enzyme, such as a-galactosidase or a-mannosidase (see Table I ).
Partially purified normal human placenta ,3-glucuronidase, prepared as described above, was used as the standard blocking enzyme and as the standard indicator enzyme. The buffer used to dilute Sepharose preparations, standard or test blocking enzyme solutions, and standard indicator enzyme solutions was 0.02 M Tris-HCl, 75 mM NaCl, pH 7.2, containing 1.0% bovine serum albumin (TSB buffer). The dilution of AS-Sepharose used in the blocking EIA was determined as follows: 0.4 ml of TSB buffer, 0.5 ml of a 1:400 dilution of standard indicator enzyme, and 0.1 ml of serial twofold dilutions of AS-Sepharose, NS-Sepharose, or TSB buffer were added to multiple screw-cap glass tubes. The tubes were mixed and incubated on a rotator at 4°C for 30 min. After centrifugation at 1,000 g for 3 min at 4°C, 0. 18 h. The AS-Sepharose was washed by centrifuging the tubes at 1,000g for 3 min at 4°C and removing all but 0.1 ml (which contained the Sepharose) by aspiration through a pipette with a short U-tip. 7.4 ml of ice-cold TSB buffer was added, the tubes were mixed and recentrifuged, and all but 0.1 ml was again aspirated. For the second (indicator) stage of the assay, 0.4 ml of TSB buffer and 0.5 ml of a 1:400 dilution of standard indicator enzyme were added to the tubes containing blocked and washed Sepharose. The tubes were mixed, incubated on a rotator at 40C for 30 min, and again centrifuged. 0.5 ml of supematant was removed and assayed for f3glucuronidase activity. Standard and test blocking enzyme were run simultaneously on every assay. The level of enzyme activity remaining in the final supernatant from the second stage of the assay was plotted against the amount of standard or test blocking enzyme activity added in the first stage of the assay.
The lower base line (no blocking in first stage) was determined by adding 0.9 ml of TSB buffer to 0.1 ml of AS-Sepharose for the first incubation (i.e., omitting blocking enzyme) and proceeding as in the first and second stages of the assay.
The theoretical upper base line (100%1o blocking in first stage) was determined by adding 0.5 ml of TSB buffer to 0.5 ml of a 1:400 dilution of standard indicator enzyme in tubes containing no AS-Sepharose and proceeding as in the second stage of the assay with the incubation at 4°C. Complete blocking in the assay would displace the curve from the lower base line to the theoretical upper base line. Percent blocking was calculated by dividing the observed displacement (units per milliliter observed -units per milliliter at lower base line) by complete displacement (units per milliliter at upper base line -units per milliliter at lower baseline), and multiplying by 100%. A diagram of the assay is shown in Fig. 1 .
Two controls were included. A control for the maximum amount of blocking enzyme bound by the AS-Sepharose in the first stage of the assay and subsequently released in the second stage (release control) was performed by substituting 0.5 ml TSB buffer for the standard indicator enzyme. A control for nonspecific binding by the AS-Sepharose was performed by substituting NS-Sepharose for AS-Sepharose in various tubes.
Due to the limited amounts of patient and heterozygote blocking enzymes available and also to the limited number of tubes that could be included in one assay because of technical considerations, each point on the blocking curves represented a single sample determination. To assess reproducibility, every test blocking enzyme was assayed at least twice. While the exact level of enzyme activity in the final supernatant for each dose of blocking enzyme varied slightly from one assay to another, the difference (or similarity) observed between test blocking curve and standard blocking curve was always consistent. The standard deviation of the enzyme assay at an enzyme level of 100 U/mn (in the working range of the EIA) was 1.8 U/ml, and coefficient of variation was 1.8%.
RESULTS
Characteristics of the blocking EIA for f3glucuroni-dase. The experimental and control curves for the standard blocking enzyme are shown in Fig. 2 . Experimental curve A rises above the upper base line, indicating that some of the enzyme bound by AS-Sepharose in the first stage of the assay is released in the second stage of the assay. Control curve B indicates that released enzyme contributes appreciably to curve A at high doses of blocking enzyme but not at low doses. While the displacement of the lower portion of curve A from the lower base line represents true blocking, the displacement of the middle to upper portions of cturve A represents a combination of true blocking and a graduially increasing component of release of blocking enzyme. One can approximate a true blocking curve by correcting for the "release phenomenon." If for each dose of blocking enzyme, the points on curve B are subtracted from curve A, a "minimum blocking curve" representing only blocking can be constructed. Since curves corrected for released enzyme (A minus B) were felt to be a considerably more accurate representation of true blocking than uncorrected curves, corrected curves were used in the data to be presented. Portions of curves not requiring correction are indicated by solid lines; portions requiring corrections are indicated by dashed lines.
Control curve C of Fig. 2 Many efforts were made to maximize the avidity of the AS-Sepharose for enzyme and thus minimize the release phenomenon. The goat was injected with low doses of immunogen on multiple occasions in an effort to enhance the avidity of the antiserum. AS-Sepharose bound enzyme activity more avidly when coupled at a ratio of 1 mg protein/ml packed Sepharose than at 10 mg/ml. Consequently, the former ratio was used. Use of Sepharose to which the purified IgG fraction of the goat antiserum was coupled at a ratio of 1 mg protein/ml packed Sepharose did not improve avidity or reduce the release phenomenon. Consequently, whole AS-Sepharose was used. The release phenomenon was reduced by carrying out the incubations of both the first and second stages ofthe assay at 4°C rather than 37°C. Additionally, the binding of enzyme activity to the AS-Sepharose was as rapid at 4°C as at 37°C. Accordingly, incubation temperatures were kept at 4°C. When the incubation during the first stage of the assay lasted 1 h, the standard blocking curve failed to reach the upper base line. Accordingly, this incubation was prolonged to 18 h. While this allowed more complete blocking of the lower affinity antigen-binding sites of the AS-Sepharose, it also enhanced the release phenomenon. Nevertheless, this latter incubation time was chosen as the best compromise methodology.
In the studies below, the assay presented in Fig. 2 Fig. 3 . Crude placenta, liver, fibroblast, and platelet enzymes were each assayed simultaneously with the partially purified placenta enzyme used as standard blocking enzyme. Enzyme from each of the four sources generated blocking curves indistinguishable from those generated by the standard blocking enzyme. Thus no antigenic differences could be detected between placenta, liver, fibroblast, and platelet enzymes with goat antiserum to the placenta enzyme.
Comparison of 1&glucuronidase from cultured fibroblasts of patients with f3glucuronidase deficiency mucopolysaccharidosis. The ability of extracts from cultured fibroblasts of patients with f-glucuronidase deficiency mucopolysaccharidosis to block in the EIA is shown in Fig. 4 of CRM. The patient fibroblast extracts contained at least as much blocking activity per amount of enzyme activity as did normal enzyme (Fig. 4) . The extract of patient 4, the most severely affected patient clinically, generated a severely compromised blocking curve. While this enzyme antigenically cross-reacted with normal enzyme, it was also deficient in the antigenic determinants present on normal enzyme. This is demonstrated by the fact that the two highest doses of blocking enzyme failed to block more than the third highest dose, indicating that the maximum blocking capacity of the CRM (approximately 36%) had been attained. The extracts of patients 2 and 3, less severely affected clinically, generated less severely compromised blocking curves. These curves demonstrated a minimum of 76% and 56% blocking, respectively, and did not reach an upper plateau at the highest available doses of blocking enzyme. The correlation between degree of blocking activity in fibroblast extracts and clinical severity is not complete. The extract of patient 1, the least affected patient clinically, generated a blocking curve demonstrating only 32% blocking. Comparison of ,3glucuronidase from cultured fibroblasts of two obligate heterozygotes for f3-glucuronidase deficiency mucopolysaccharidosis. The ability of enzyme from cultured fibroblasts of two obligate heterozygotes for B-glucuronidase deficiency (mother and father of patient 3) to block in the EIA is shown in Fig. 5 . Release controls performed with these extracts indicated that no enzyme activity was released from the blocked and washed AS-Sepharose during the second stage, except for the two highest doses of the father's extract. Thus the blocking curves obtained with heterozygotes' fibroblast extracts did not require correction except at those two points. Fibroblast extracts from both heterozygotes blocked in the EIA. Both fibroblast enzymes contained at least as much blocking activity per amount of enzyme activity as did normal enzyme (Fig. 5) . This result would be expected if the heterozygote fibroblasts contained both normal and mutant enzyme. Since /3-glucuronidase is a tetramer (19) (20) (21) , the heterozygote enzyme most likely represents varying combinations of normal and abnormal monomers in a tetrameric enzyme (22 cannot be attributed to bovine enzyme taken up from fetal calf serum for two reasons. For bovine enzyme to produce the degree of blocking observed would require the addition of 100 times the amount ofenzymatic activity present in the mutant extracts. Furthermore, the uptake of CRM from the heat-inactivated fetal calf serum is unlikely because the blocking activity of bovine enzyme was completely eliminated by the thermal inactivation used to destroy the ,&glucuroni-dase activity in fetal calf serum. ,8-Glucuronidase from different human tissue sources is known to be heterogeneous electrophoretically and to vary in the proportion of high and low in vitro "uptake" forms (12, 23) . However, no antigenic differences could be detected by the EIA when studied with an antiserum against the placental enzyme. The placental enzyme is predominantly the low-uptake form. It is possible that antibody to the high-uptake form of the enzyme, which has characteristic isoelectric properties (23) , might distinguish antigenic determinants not shared by other forms of the enzyme.
These studies extend experience with the blocking EIA described by Neuwelt et al. (15) for arylsulfatase Cross-Reactive Antigen in /3-Glucuronidase Deficiency A to the assay of mutant and other forms of f3-glucuronidase. The chief advantage of the EIA is that it requires neither pure antigen nor monospecific antibody. However, the assay has some limitations. The most troublesome feature of the assay described was the release phenomenon. Whether or not this phenomenon was a problem in the initial description of the method (15) is uncertain. In that report, two of the blocking curves with normal enzymes appeared to reach an uipper plateau at the upper base line, which suggests that there was little, if any, release. However, many of the other blocking curves did not reach an uipper plateaut and failed to reach the uipper base line.
The control, in which blocked and washed AS-Sepharose was incubated in buffer alone, was not reported (15) . The release phenomenon may have been prominent in our assay because the initial stage of incubation of AS-Sepharose with blocking enzyme was prolonged to 18 h. This allowed enzyme to be bound to a higher proportion of lower affinity sites. While this improved the sensitivity of the assay, it also enhanced the release phenomenon.
The explanation for the absence of the release phenomenon with the patients' fibroblast extracts (Fig. 3) is uncertain. This could be related at least in part to the dose of blocking enzyme activity added. Release was not observed with standard blocking enzyme until a dose of at least 100 U had been added (Fig. 4) . A dose this high was not reached with the patients' extracts.
It would appear that a high-avidity antiserum is of utmost importance to the success of this assay. The sensitivity of our assay was greater and the release phenomenon less with the goat antiserum used than with a rabbit antiserum we tried initially. A possible explanation may be inferred from Fig. 6 . The close antigenic similarity between the rabbit and human liver enzymes suggests that rabbits might have recognized fewer antigenic determinants in the htuman enzyme as foreign than did the goat, which produced an antiserum of greater avidity. Even with the more avid goat antiserum, the release phenomenon could not be completely eliminated. In spite of the indicated limitations of the EIA, it is clear from these studies that this assay provided useful information in a system where neither pure antigen nor monospecific antiserum was available.
The CRM in extracts of fibroblasts from ,3-glucuronidase-deficient patients is a favorable finding from the standpoint of immunological acceptance of enzyme replacement therapy in such patients. An immune response directed against infused enzyme could lead to treatment failure or to iatrogenic disease (14) . However, whether or not these patients possess sufficient CRM to obviate an immune response to infused enzyme cannot be determined from this study.
